Date published: 2025-10-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

A33 Inhibitors

A33 inhibitors belong to a distinct chemical class that has garnered considerable attention in the field of biomedicine and pharmacology. These inhibitors are characterized by their specific ability to target and modulate the function of a membrane-bound glycoprotein known as A33. This glycoprotein, also referred to as GpA33, is predominantly expressed in certain tissues and organs, making it an intriguing target for research and drug development. The chemical structure of A33 inhibitors is diverse, yet they share a common feature: their ability to interact selectively with the A33 glycoprotein. This interaction occurs at a molecular level, primarily through reversible binding interactions between the inhibitor and specific binding sites on the surface of A33. The mechanism of action of A33 inhibitors is still under investigation, as researchers strive to uncover the intricacies of the A33 protein's function and its interplay with various cellular processes. Preliminary studies suggest that the binding of A33 inhibitors to the glycoprotein may interfere with its interactions with other cellular components, leading to downstream effects on signal transduction pathways or cellular adhesion processes. Researchers have synthesized and characterized a diverse range of A33 inhibitors, employing cutting-edge techniques such as combinatorial chemistry and computer-assisted drug design. The development of A33 inhibitors is not limited to medicinal chemistry alone but also extends to computational modeling, structural biology, and other interdisciplinary fields. Through a combination of computational algorithms, molecular simulations, and X-ray crystallography, researchers have been able to gain insights into the three-dimensional structure of the A33 protein and its interactions with various inhibitors. This knowledge is crucial for the rational design and optimization of A33 inhibitors with enhanced binding affinity and improved pharmacokinetic properties. The applications of A33 inhibitors span beyond the realms of medicine, offering new opportunities in areas such as basic research, diagnostics, and imaging. By exploiting the selective binding properties of A33 inhibitors, researchers have successfully developed diagnostic tools and imaging agents that can specifically detect and visualize A33 expression in tissues and cells. This has proven invaluable in the field of molecular imaging, allowing for the non-invasive monitoring of A33 expression patterns and the assessment of its role in various physiological and pathological conditions.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

A broad-spectrum protein kinase inhibitor, suppressing various signaling pathways including those associated with A33, potentially inhibiting downstream targets and leading to the suppression of A33 activity.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Inhibits phosphoinositide 3-kinases (PI3K), disrupting PI3K/Akt signaling pathway, which can indirectly down-regulate A33 expression or activity by interfering with the associated intracellular signaling cascades.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

Another inhibitor of PI3K, disrupting PI3K/Akt signaling pathway, which may indirectly suppress A33 expression or activity by interrupting the associated intracellular signaling cascades.

AZD5363

1143532-39-1sc-503190
5 mg
$309.00
(0)

A selective inhibitor of Akt, blocking Akt-mediated signaling pathways, potentially leading to the inhibition of downstream targets including A33.

GSK 690693

937174-76-0sc-363280
sc-363280A
10 mg
50 mg
$255.00
$1071.00
4
(1)

Inhibits Akt, a key player in the PI3K/Akt signaling pathway, which can indirectly affect A33 expression or activity by disrupting downstream signaling events involved in its regulation.

BKM120

944396-07-0sc-364437
sc-364437A
sc-364437B
sc-364437C
5 mg
10 mg
25 mg
50 mg
$173.00
$230.00
$275.00
$332.00
9
(0)

A pan-class I PI3K inhibitor, targeting PI3K isoforms, and thereby disrupting PI3K/Akt signaling pathway, which may indirectly suppress A33 expression or activity by interfering with the associated intracellular signaling cascades.

Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2

612847-09-3sc-202048
sc-202048A
1 mg
5 mg
$204.00
$265.00
29
(1)

A potent Akt inhibitor, blocking Akt-mediated signaling pathways, which could lead to the inhibition of downstream targets including A33.

PI-103

371935-74-9sc-203193
sc-203193A
1 mg
5 mg
$32.00
$128.00
3
(1)

A dual PI3K/mTOR inhibitor, blocking PI3K/Akt/mTOR signaling pathway, which can indirectly affect A33 expression or activity by interrupting the associated intracellular signaling cascades.

GDC-0941

957054-30-7sc-364498
sc-364498A
5 mg
10 mg
$184.00
$195.00
2
(1)

Inhibits PI3K, disrupting PI3K/Akt signaling pathway, potentially leading to the suppression of downstream targets including A33.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Inhibits mTOR, a downstream effector in the PI3K/Akt signaling pathway, which may indirectly down-regulate A33 expression or activity by interfering with the mTOR-dependent regulation of protein synthesis and cell growth.